NFKB1 and cancer: For example, IKKα has been proposed to promote mammalian target of rapamycin complex 1 (mTORC1) and mTORC2 activity via feedforward signalling, and thus could serve as a therapeutic target in mTOR-dependent cancers in a manner independent of potent canonical NF-κB inhibition [239,240].